Statutory auditor

Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma

Retrieved on: 
Monday, October 30, 2023
Linda, Euronext, International Financial Reporting Standards, Galapagos NV, International Air Transport Association code, Thirty-second Amendment of the Constitution Bill 2013, International, Committee, Filgotinib, Workforce, News, Acquisition, Related party transaction, UK, Statutory auditor, CET, Collaboration, CFO, European, Patient, Letter, Cryptocurrency, Pharmaceutical industry, Management, Commercial property, Audit, Pamlab, Galápagos Islands

Galapagos will pay up to €40 million by June 2025 to Alfasigma for Jyseleca® related development activities.

Key Points: 
  • Galapagos will pay up to €40 million by June 2025 to Alfasigma for Jyseleca® related development activities.
  • “Today’s news is the result of a thoughtful, in-depth analysis, and represents the successful conclusion of the strategic evaluation process for Jyseleca®.
  • The acquisition of Galapagos' Jyseleca® business represents another important milestone in Alfasigma's international transformation and growth path and fits perfectly with our Company's core business areas.
  • It is the intention in the contemplated transaction between Galapagos and Alfasigma that the amended Filgotinib Agreement will be assigned by Galapagos to Alfasigma.

Affluent Medical : H1 2023 results. Major advances in clinical programs. Extension of cash horizon to February 2024.

Retrieved on: 
Thursday, September 28, 2023
Artus, NYHA, US Foods, Urinary incontinence, Disease, Human, Statutory auditor, Tricuspid valve, Myocardial infarction, DSMB, Butterfly valve, Hospital, Boston Scientific, Bank statement, Abbott, Anatomy, Aortic stenosis, Food, Clinical trial, Optimization, Quality of life, Minerva, MR, Kalio, Doctor of Philosophy, TAVI, New York Heart Association Functional Classification, Medtronic, Mitral regurgitation, MD, Patient, Mitral valve, Risk, Data, CEST, Engineering, Regulatory News Service, ISIN, DSM-IV codes, Neurostimulation, FDA, Death, Aix-en-Provence, III, Medtech, Pharmaceutical industry, Medical imaging, Medical device, Nursing, Fine chemical, Science

Since early 2023, Affluent Medical has been developing its medical devices and announced important clinical advances in each of its three programs.

Key Points: 
  • Since early 2023, Affluent Medical has been developing its medical devices and announced important clinical advances in each of its three programs.
  • This transcatheter approach avoids an invasive "open heart" procedure and associated complications to treat mitral valve insufficiency.
  • Affluent Medical believes that Kalios would avoid further intervention for potentially 30-40% of patients over a five-year horizon.
  • This transaction would be intended to finance ongoing clinical programs and could receive the support of its reference shareholders.

EQS-News: Affluent Medical SA: H1 2023 RESULTS - Major advances in clinical programs - Extension of cash horizon to February 2024

Retrieved on: 
Thursday, September 28, 2023
Artus, NYHA, US Foods, Urinary incontinence, Disease, Human, Statutory auditor, Tricuspid valve, Myocardial infarction, DSMB, Butterfly valve, Hospital, Boston Scientific, Bank statement, Abbott, Anatomy, Aortic stenosis, Food, Clinical trial, Optimization, Quality of life, Minerva, MR, Kalio, Doctor of Philosophy, TAVI, New York Heart Association Functional Classification, Medtronic, Mitral regurgitation, MD, Patient, Mitral valve, Risk, Data, CEST, Engineering, ISIN, DSM-IV codes, Neurostimulation, FDA, Death, Aix-en-Provence, III, Medtech, Medical imaging, Medical device, Pharmaceutical industry, Nursing, Fine chemical, Science

Since early 2023, Affluent Medical has been developing its medical devices and announced important clinical advances in each of its three programs.

Key Points: 
  • Since early 2023, Affluent Medical has been developing its medical devices and announced important clinical advances in each of its three programs.
  • In March 2023, Affluent Medical announced the successful first implantation of the Epygon biomimetic mitral heart valve in a patient with a severe mitral valve insufficiency profile combined with several comorbidity factors.
  • Affluent Medical believes that Kalios would avoid further intervention for potentially 30-40% of patients over a five-year horizon.
  • This transaction would be intended to finance ongoing clinical programs and could receive the support of its reference shareholders.

Transgene Advances Its Innovative Immunotherapy Pipeline and Extends Financial Visibility Until the End of 2024

Retrieved on: 
Wednesday, September 20, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Oncology, MSD, Head, MBA, Phase II, Doctor of Philosophy, Journal, Patient, Potyvirus, Epitope, Merck, NEC, La Jolla Institute for Immunology, FRCP, University, HPV16, Research, Lung cancer, Merck & Co., De novo, University of Liverpool, CD8, Cervical cancer, CTL, Biology, Immunology, Phase, Safety, AACR, E6, Immune system, University of Lausanne, European Journal, KOL, European Journal of Cancer Prevention, Bank statement, AstraZeneca, E7, ASCO, Euronext Paris, Statutory auditor, Combined, Immunotherapy, Tumor microenvironment, Pharmaceutical industry, Vaccine, Computer data storage, Cancer, MD, TG4050, Transgene

We are planning together with our partner NEC to start a randomized Phase II trial in 2024.

Key Points: 
  • We are planning together with our partner NEC to start a randomized Phase II trial in 2024.
  • Transgene and NEC intend to start a randomized Phase II trial in the adjuvant setting of head and neck cancer in 2024.
  • Transgene is assessing all options to ensure data read out in 2024 from the trial as previously communicated.
  • The Board of Directors of Transgene met on September 20, 2023, and approved the financial statements for the six-month period ended June 30, 2023.

Kaufman & Broad SA: AVAILABILITY OF THE 2023 THE HALF YEARLY INTERIM FINANCIAL REPORT

Retrieved on: 
Thursday, July 27, 2023
Regulatory News Service, AMF, Interim, Statutory auditor, Audit

Dissemination of a French Regulatory News, transmitted by EQS Group.

Key Points: 
  • Dissemination of a French Regulatory News, transmitted by EQS Group.
  • The issuer is solely responsible for the content of this announcement.
  • Kaufman & Broad SA announces that its half-yearly interim financial report of May 31, 2023 has been made available to the public and filed with the "Autorité des Marchés Financiers" (AMF)
    the half-yearly consolidated financial statements;
    the statement by the person responsible for the half-yearly financial report;
    the Statutory Auditors' report on the review of the half-yearly consolidated financial statements.
  • This document is available in French, under the conditions defined by the current laws and regulations and may be consulted as follows:
    Click here to access the 2023 half yearly Interim Financial Report.

RUBIS: Minutes of the Combined Shareholders’ Meeting of 8 June 2023

Retrieved on: 
Saturday, June 10, 2023
Statutory auditor, Financial Oversight and Management Board for Puerto Rico v. Aurelius Investment, LLC, Shareholder, FY, Bank statement, Supervisory board, Mass meeting, CSR, Share repurchase, Salle Wagram, Management, Combined, Holding company

The Combined Shareholders’ Meeting of Rubis was held on Thursday 8 June 2023, at 2.00 p.m. at Salle Wagram, 39 avenue de Wagram, 75017 Paris, France and chaired by Mr Gilles Gobin.

Key Points: 
  • The Combined Shareholders’ Meeting of Rubis was held on Thursday 8 June 2023, at 2.00 p.m. at Salle Wagram, 39 avenue de Wagram, 75017 Paris, France and chaired by Mr Gilles Gobin.
  • This Shareholders’ Meeting was webcast live on the Company's website ( www.rubis.fr/en ) and remains available for replay on this website, via the following link: https://channel.royalcast.com/rubisfr/#!/rubisfr/20230608_1 .
  • Activities, financial results, performance and strategy, including a focus on the CSR approach and, in particular, the climate strategy, were presented to shareholders by the Management.
  • The detailed outcome of the votes will soon be published on the Company's website (( www.rubis.fr/en ) under the tab "Shareholders - General Meeting - General Meeting June 08, 2023 - Other Documents”.

Samba Digital, Inc: FINAL RESULTS 2022

Retrieved on: 
Wednesday, May 3, 2023
Statutory auditor, Regulatory News Service, CMVM, Euronext Lisbon, Security (finance)

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • Sales 2022: +37% - Net profit 2022: +56%.
  • Lisbon (Portugal) – 3 May 2023 – 6 p.m.: Samba Digital, a global player in sports marketing, announces its final 2022 results with a clear increase.
  • The final 2022 accounts, audited by the Statutory Auditors and published on 28 April 2023 with the CMVM (Lisbon Stock Exchange regulatory authority), are as follows:

RUBIS: Publication of the 2022 Universal Registration Document

Retrieved on: 
Monday, May 1, 2023
Statutory auditor, Bank statement, Supervisory board, Publication, Share repurchase, Rubis, Regulatory News Service, AMF, Property management, Audit, ESEF

Rubis filed its 2022 Universal Registration Document with the Autorité des marchés financiers (the French Financial Markets Authority – AMF), in ESEF format, on 28 April 2023.

Key Points: 
  • Rubis filed its 2022 Universal Registration Document with the Autorité des marchés financiers (the French Financial Markets Authority – AMF), in ESEF format, on 28 April 2023.
  • This document is available on the Company's website ( www.rubis.fr/en ) in the section "Publications – Financial Reports – Universal Registration Documents", on the AMF’s website ( www.amf-france.org ) and at the company's registered office (46, rue Boissière - 75116 Paris - France).
  • The Annual Financial Report’s cross-reference table is displayed on page 321 of the 2022 Universal Registration Document.
  • The English version of the 2022 Universal Registration Document will soon be released on the Company’s website.

GENFIT Announces Publication of the 2022 Universal Registration Document and the 2022 Annual Report on Form 20-F

Retrieved on: 
Tuesday, April 18, 2023
Statutory auditor, Bank statement, Statute, Patient, Annual report, Chronic liver disease, AMF, Audit, Euronext

Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); April 18, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced the filing of its 2022 Universal Registration Document with the Autorité des marchés financiers (AMF) and its Annual Report on Form 20-F for the year ended December 31, 2022 with the U.S. Securities and Exchange Commission (SEC).

Key Points: 
  • Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); April 18, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced the filing of its 2022 Universal Registration Document with the Autorité des marchés financiers (AMF) and its Annual Report on Form 20-F for the year ended December 31, 2022 with the U.S. Securities and Exchange Commission (SEC).
  • These annual reports are available to the public free of charge in accordance with applicable regulations and may be viewed at and downloaded from GENFIT’s website at ir.genfit.com .
  • The 2022 Registration Document is also available on the AMF’s website: www.amf-france.org and the Annual Report on Form 20-F is available on the website of the SEC ( www.sec.gov ).
  • GENFIT’s 2022 Universal Registration Document includes, in particular:
    the annual Board of Directors’ management report,
    the Board of Directors’ report on corporate governance,
    the Statutory Auditors’ reports on the annual and consolidated financial statements and related-party agreements, and
    the table summarizing the fees paid to the Statutory Auditors.

Annual General Meeting of Julius Baer Group Ltd.

Retrieved on: 
Saturday, April 15, 2023
Executive, Statutory auditor, Eunice, Annual, AGM, Mass meeting, Financial statement, Article, Share repurchase, National Executive Board of the Boy Scouts of America, Law, Consolidated, KPMG, Professional Football Compensation Committee, CHF, Remuneration, Compensated emancipation, Nomination, Audit, Holding company, Management, Financial adviser

Annual General Meeting of Julius Baer Group Ltd.

Key Points: 
  • Annual General Meeting of Julius Baer Group Ltd.
    Zurich, 13 April 2023 – At today’s Annual General Meeting of Julius Baer Group Ltd. the shareholders passed all agenda items and proposals submitted by the Board of Directors.
  • In detail, the Annual General Meeting 2023 of Julius Baer Group Ltd. passed the following resolutions:
    The Financial Statements and Consolidated Financial Statements 2022 were approved and the Remuneration Report 2022 was approved in a consultative vote.
  • The dividend is subject to the Swiss withholding tax and shall be paid from 19 April 2023.
  • Marc Nater, Wenger Plattner Attorneys at Law, Kuesnacht, was elected as independent representative until the end of the next Ordinary Annual General Meeting in 2024.